Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foreign Pharmas Abandon 23 New Drug Projects In Japan In Past 10 Years

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Twelve foreign pharmaceutical manufacturers with permanent establishments in Japan have abandoned a total of 23 drug development projects in Japan over the past 10 years, an official of the Federation of Pharmaceutical Manufacturers' Association of Japan, said Oct. 30

You may also be interested in...



Japan’s Pharma Industry Proposes Plans To Reform Drug Pricing System

TOKYO - The Japanese pharmaceutical industry has been in talks with the government over an industry proposal on ways to better sustain the price of novel drugs released in the country

Japan’s Pharma Industry Proposes Plans To Reform Drug Pricing System

TOKYO - The Japanese pharmaceutical industry has been in talks with the government over an industry proposal on ways to better sustain the price of novel drugs released in the country

Novartis Sees Opportunities In Financial Crisis, CEO Tells Tokyo Business Group

TOKYO - Novartis CEO Daniel Vasella told an audience in Tokyo last week that "the current [global financial] situation creates opportunities because [Novartis has] a very solid free cash flow and most [Novartis] companies have a solid free cash flow and are not in a highly indebted environment.

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel